Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesAnti-U11/U12 RNP antibodies in systemic sclerosis: A new serologic marker associated with pulmonary fibrosis
Arthritis Care and Research , 07/09/09
Fertig N et al. – Study reports that anti-U11/U12 RNP antibodies were present in the sera of approximately 3% of patients with systemic sclerosis (SSc) and were a marker for lung fibrosis, which is often severe.
Methods- Identification of clinical features associated with a new serum autoantibody against U11/U12 RNP in SSc pts
- Antibody specificity and prevelance was confirmed by immunoprecipitation, RT-PCR, and Southern blotting
- Anti-U11/U12 RNP autoantibody-positive and negative SSc pts were compared based on demographic, disease classification, clinical variables, and survival
- 33 pts with anti-U11/U12 RNP antibodies were identified
- In 2 consecutive series of SSc pts first seen at 10-yr intervals (1994-1995 and 2004-2005), prevalence of antibody-positive pts was 3.2%; 52% of these had limited cutaneous involvement
- All pts had Raynaud's phenomenon and 82% had GI involvement
- None had intrinsic pulmonary arterial hypertension
- Most significant clinical difference between Ab-positive and negative cohorts was the prevalence of lung fibrosis (79%) in positive pts
- GI involvement was also significantly increased in Ab-positive group
- Pts with RNP Ab and pulmonary fibrosis had a 2.25-fold greater risk of death than negative pts with pulmonary fibrosis
Today in Connective Tissue Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis
Journal of Rheumatology, 12/04/09
Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study
Arthritis & Rheumatism, 12/03/09
Telangiectases in scleroderma: A potential clinical marker of pulmonary arterial hypertension
Journal of Rheumatology, 12/03/09
Sponsor
Article Search
Sponsor